You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 15, 2024

DrugPatentWatch Database Updates: New Patent Additions

✉ Email this page to a colleague

« Back to Dashboard

DrugPatentWatch Database Updates: New Patent Additions

These are patents which have been reported by the FDA since the last major update; they are not yet in the main database.

+ Get email alerts for changes to this table

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Number	Approval Date	Type	RLD	Patent No.	Product	Substance	Delist Requested	Patent Expiration	Date Submitted	Usecode	Patented / Exclusive Use
Vanda Pharms Inc	HETLIOZ	tasimelteon	CAPSULE	205677	001	Jan 31, 2014	RX	Yes	⤷ Sign Up				⤷ Sign Up	2024-04-04	U-3342	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY AVOIDING THE ADMINISTRATION OF TASIMELTEON WITH BETA-ADRENERGIC RECEPTOR ANTAGONISTS
Vanda Pharms Inc	HETLIOZ	tasimelteon	CAPSULE	205677	001	Jan 31, 2014	RX	Yes	⤷ Sign Up				⤷ Sign Up	2024-04-04	U-3343	TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY AVOIDING THE ADMINISTRATION OF TASIMELTEON WITH BETA-ADRENERGIC RECEPTOR ANTAGONISTS
Vanda Pharms Inc	HETLIOZ	tasimelteon	CAPSULE	205677	001	Jan 31, 2014	RX	Yes	⤷ Sign Up				⤷ Sign Up	2024-04-04	U-3003	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY ADMINISTERING TASIMELTEON
Vanda Pharms Inc	HETLIOZ	tasimelteon	CAPSULE	205677	001	Jan 31, 2014	RX	Yes	⤷ Sign Up				⤷ Sign Up	2024-04-04	U-3865	TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY ADMINISTERING TASIMELTEON
Vanda Pharms Inc	HETLIOZ LQ	tasimelteon	SUSPENSION	214517	001	Dec 1, 2020	RX	Yes	⤷ Sign Up				⤷ Sign Up	2024-04-04	U-3342	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY AVOIDING THE ADMINISTRATION OF TASIMELTEON WITH BETA-ADRENERGIC RECEPTOR ANTAGONISTS
Vanda Pharms Inc	HETLIOZ LQ	tasimelteon	SUSPENSION	214517	001	Dec 1, 2020	RX	Yes	⤷ Sign Up				⤷ Sign Up	2024-04-04	U-3003	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY ADMINISTERING TASIMELTEON
Arcutis	ZORYVE	roflumilast	FOAM	217242	001	Dec 15, 2023	RX	Yes	⤷ Sign Up				⤷ Sign Up	2024-07-10	U-3773	TOPICAL TREATMENT OF SEBORRHEIC DERMATITIS IN PATIENTS 9 YEARS OF AGE AND OLDER
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Number	>Approval Date	>Type	>RLD	>Patent No.	>Product	>Substance	>Delist Requested	>Patent Expiration	>Date Submitted	>Usecode	>Patented / Exclusive Use

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.